Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%
Artiva Biotherapeutics halted its experimental cell therapy AlloNK after two patient deaths in a mid-stage trial. The company will cut 94% of its workforce and explore strategic alternatives. Shares fell 30% in premarket trading. As of September 30, Artiva had $319.1 million in cash and investments.
How this was made
The 30-second read
Why it matters
The abrupt halt likely triggers a sharp sell‑off in Artiva’s equity and may pressure peer cell‑therapy stocks.
Market read
First‑report disclosure of a major clinical‑trial failure and workforce reduction, creating immediate trading relevance for the company and sector.
What to watch
Cash runway of $319 million may allow pivot to other programs, mitigating downside.
Background
Artiva Biotherapeutics announced the termination of its AlloNK cell‑therapy after two patient deaths, cutting its workforce by 94% and exploring strategic alternatives.
Market effects
Biotech sector may see heightened risk perception for cell‑therapy programs.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Potential buyer could acquire assets at discount if strategic alternatives include a sale.
Key entities
- companyArtiva Biotherapeutics
Developer of AlloNK cell‑therapy, now discontinuing the program.
- executiveFred Aslan
CEO of Artiva Biotherapeutics, announced the decision.
